Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Total Liabilities (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Total Liabilities for 16 consecutive years, with $543.4 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 388.1% to $543.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $543.4 million through Dec 2025, up 388.1% year-over-year, with the annual reading at $543.4 million for FY2025, 388.1% up from the prior year.
  • Total Liabilities hit $543.4 million in Q4 2025 for Ligand Pharmaceuticals, up from $526.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $549.3 million in Q1 2021 to a low of $86.3 million in Q4 2023.
  • Historically, Total Liabilities has averaged $255.6 million across 5 years, with a median of $165.0 million in 2022.
  • Biggest five-year swings in Total Liabilities: plummeted 65.97% in 2023 and later soared 388.1% in 2025.
  • Year by year, Total Liabilities stood at $476.4 million in 2021, then tumbled by 65.33% to $165.2 million in 2022, then plummeted by 47.75% to $86.3 million in 2023, then grew by 29.0% to $111.3 million in 2024, then skyrocketed by 388.1% to $543.4 million in 2025.
  • Business Quant data shows Total Liabilities for LGNDZ at $543.4 million in Q4 2025, $526.6 million in Q3 2025, and $120.1 million in Q2 2025.